Literature DB >> 7826212

The nucleoprotein of Pichinde virus expressed by a vaccinia-Pichinde virus recombinant partially protects hamsters from lethal virus challenge.

D Y Ozols1, W E Rawls, K L Rosenthal, D G Harnish.   

Abstract

Syrian hamsters, strain MHA/Lak, are susceptible to intraperitoneal infection with Pichinde virus and die from an overwhelming viremia. We have studied the ability of a vaccinia-Pichinde recombinant virus expressing amino acids 51-561 of the viral nucleoprotein (VVNP51-561) to protect from lethal Pichinde virus infection. Priming with VVNP51-561 significantly delayed mortality and increased final survival outcome after challenge with 2 x 10(3) pfu of Pichinde virus. This protection was not complete compared to priming with Pichinde virus in the footpad, which was not lethal and provided 100% protection. At a higher challenge dose of Pichinde virus, 2 x 10(4) pfu, immunization with VVNP51-561 delayed mortality but did not increase final survival. The partial protection correlated with an early but not late reduction in infectious virus in serum, kidney and liver, and infectious centers in the spleen. Thus the immune response generated by VVNP51-561 could initially control the infection, effectively reducing the virus inoculum. As the infection proceeded, virus replication could not be limited resulting in death in some hamsters. The partial protection did not appear to be mediated by anti-viral antibodies since these were not detected in the serum of VVNP56-561-immunized hamsters. This finding appears to support the hypothesis that in many arenavirus infections cellular immunity is central to viral clearance and protection from reinfection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7826212     DOI: 10.1007/bf01309452

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  34 in total

1.  Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques.

Authors:  K T McKee; J G Oro; A I Kuehne; J A Spisso; B G Mahlandt
Journal:  Intervirology       Date:  1992       Impact factor: 1.763

2.  Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection.

Authors:  L S Klavinskis; J L Whitton; M B Oldstone
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

3.  Clinical virology of Lassa fever in hospitalized patients.

Authors:  K M Johnson; J B McCormick; P A Webb; E S Smith; L H Elliott; I J King
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

4.  Antiviral action of immune lymphocytes in mice infected with lymphocytic choriomeningitis virus.

Authors:  C A Mims; R V Blanden
Journal:  Infect Immun       Date:  1972-11       Impact factor: 3.441

5.  Immunofluorescence study of the mechanism of resistance to superinfection in mice carrying the lymphocytic choriomeningitis virus.

Authors:  C A Mims; T P Subrahmanyan
Journal:  J Pathol Bacteriol       Date:  1966-04

6.  Differences between Syrian hamster strains in natural killer cell activity induced by infection with Pichinde virus.

Authors:  S R Gee; D A Clark; W E Rawls
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

7.  Pichindé virus, a new virus of the Tacaribe group from Colombia.

Authors:  H Trapido; C Sanmartín
Journal:  Am J Trop Med Hyg       Date:  1971-07       Impact factor: 2.345

8.  Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection.

Authors:  D D Auperin; J J Esposito; J V Lange; S P Bauer; J Knight; D R Sasso; J B McCormick
Journal:  Virus Res       Date:  1988-02       Impact factor: 3.303

9.  Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever.

Authors:  J C Clegg; G Lloyd
Journal:  Lancet       Date:  1987-07-25       Impact factor: 79.321

10.  Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus.

Authors:  H G Morrison; S P Bauer; J V Lange; J J Esposito; J B McCormick; D D Auperin
Journal:  Virology       Date:  1989-07       Impact factor: 3.616

View more
  1 in total

1.  A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease.

Authors:  S D Dowall; K R Buttigieg; S J D Findlay-Wilson; E Rayner; G Pearson; A Miloszewska; V A Graham; M W Carroll; R Hewson
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.